D46.22
Refractory anemia with excess of blasts 2
Clinical Classification Guidelines
Inclusion Terms
- RAEB 2
Medical Intelligence & Overview
Refractory Anemia with Excess of Blasts 2, coded as D46.22 in the ICD-10 classification, is a type of myelodysplastic syndrome (MDS). It is characterized by abnormal development of blood cells in the bone marrow, leading to a build-up of immature cells called blasts. This condition represents a more advanced stage of MDS and has a higher potential to progress to acute myeloid leukemia (AML). Patients often present with symptoms related to anemia, increased risk of infections, and bleeding tendencies due to dysfunctional blood cell production.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting the bone marrow's ability to produce healthy blood cells Exposure to environmental toxins or radiation Previous chemotherapy or radiation therapy for cancer Certain hereditary conditions that impact blood cell development Unknown factors in many cases where no specific cause is identified
Key Symptoms: Fatigue and weakness due to anemia Increased susceptibility to infections Easy bruising or bleeding, including nosebleeds or bleeding gums Shortness of breath during exertion Pale skin or pallor Unexplained weight loss or fever
Diagnostic & Treatment
Diagnosis Path: Diagnosing RAEB-2 involves a combination of blood tests and bone marrow examination. Key diagnostic steps include: - Complete blood count (CBC) revealing low levels of red blood cells, and sometimes abnormal white blood cells or platelets - Bone marrow biopsy showing an increased number of blasts (between 10% and 19%) among immature blood cells - Cytogenetic analysis to identify chromosomal abnormalities - Additional tests to rule out other hematologic conditions The presence of 10-19% blasts in the bone marrow distinguishes RAEB-2 from other myelodysplastic syndromes with lower blast counts.
Treatment Protocols: Treatment options for RAEB-2 aim to manage symptoms, reduce the risk of progression, and potentially achieve remission. These include: - Hypomethylating agents such as azacitidine or decitabine to modify abnormal blood cell growth - Supportive care with blood transfusions to address anemia or platelet deficiencies - Antibiotics or growth factors to reduce infection risk and support blood cell production - Allogeneic stem cell transplantation may be considered in suitable candidates, offering a potential cure - Enrollment in clinical trials exploring new therapies Treatment plans are tailored to each patient's overall health, age, and disease severity.
Clinical Advice & FAQs
Billing Guidance
Is D46.22 a billable ICD-10 code?
Yes, D46.22 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D46.22?
Clinical documentation must specify the nature of Refractory anemia with excess of blasts 2 and any associated comorbidities for accurate reporting.
Cite this Clinical Reference